Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

BACKGROUND: We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC).The pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Moran, Teresa, Felip, Enriqueta, Keedy, Vicki, Borghaei, Hossein, Shepherd, Frances A, Insa, Amelia, Brown, Holly, Fitzgerald, Timothy, Sathyanarayanan, Sriram, Reilly, John F, Mauro, David, Hsu, Karl, Yan, Li, Johnson, David H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237770/
https://www.ncbi.nlm.nih.gov/pubmed/25414803
http://dx.doi.org/10.1186/2162-3619-3-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237770/
https://www.ncbi.nlm.nih.gov/pubmed/25414803
http://dx.doi.org/10.1186/2162-3619-3-26

Ejemplares similares